Gastrointestinal oncology-therapy update 2008/2009;Gastrointestinale onkologie-therapieupdate 2008/2009

Zeitschrift fur Gastroenterologie

Volumn 47, Issue 3, 2009, Pages 296-306

  Ebert, M P ^a,b   Auernhammer, C ^a   Caca, K ^a   Eckel, F ^a   Fischbach, W ^a   Gelssler, M ^a   Goke B ^a   Greten, T ^a   Kubkka, S ^a   Lutz, M P ^a   Mohler M ^a   Opttz, O ^a   Pavel, M ^a   Porschen, R ^a   Reinacher Schick, A ^a   Schmiegel, W ^a   Seufferiein, T ^a   Wiedenmann, B ^a   Schmid, R M ^a  

^a Die Institutsangaben Sind am Ende des Beitrags Gelistet ^*  (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Colorectal cancer; Gastro entero pancreatic tumours; Oncology; Stomach cancer; Tumour therapy

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ALPHA INTERFERON; BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CHLOROTRIANISENE; CISPLATIN; DOCETAXEL; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; NAVELBINE; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PRAVASTATIN; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; THYMOSTIMULIN; TRASTUZUMAB;

BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; ESOPHAGUS CARCINOMA; GASTROINTESTINAL LYMPHOMA; GASTROINTESTINAL TRACT; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LYMPHOMA; NEUROENDOCRINE TUMOR; NEUTROPENIA; ONCOLOGY; PALLIATIVE THERAPY; PANCREAS CARCINOMA; PERIOPERATIVE PERIOD; REVIEW; STOMACH CANCER;

COMBINED MODALITY THERAPY; GASTROINTESTINAL NEOPLASMS; HUMANS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC;

EID: 64349117392     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027989     Document Type: Review

References (101)

1. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease? Semin Radiat Oncol 2007; 17: 38-44
2. Groth SS, Whitson BA, Li Z et al Determination of the ideal number of lymph nodes to examine to optimize survival in patients with esophageal carcinoma: Data from the surveillance epidemiology and end results database. J Clin Oncol 2008; 26: A4528
3. Pech O, May A. Gossner I et al Curative endoscopic therapy in patients with early esophageal squamous-cell carcinoma or high-grade intraepithelial neoplasia. Endoscopy 2007; 39: 30-35
4. Ishii N, Tsukamoto M, Izuka Y et al. Endoscopic Submucosal Dissection Is a Safe and Effective Treatment for Superficial Esophageal Cancer. First Results in a Primary Hospital. Gastrointestinal Endoscopy 2008; 67: A184
5. Deprez PH. Yeung RC. Aouattah T et al Prospective Randomized Comparison Between EMR and ESD for Endoscopic Removal of Superficial Esophageal Cancer. Gastrointestinal Endoscopy 2008; 67: A187
6. Shimada H, Nabeya Y, Matsubara H et al Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers. Am J Surg 2006; 191: 250-254
7. Konda VJ, Chennat JS, Ross AS et al Low Rate of Invasive Cancer in Patients Undergoing Mucosectomy for Barrett's Esophagus (BE) and High Grade Dysplasia (HGD) Or Intramucosal Carcinoma (IMC). Gastrointestinal Endoscopy 2008; 67: A76
8. Oyama T, Kitamura Y, Hotta K. Long Term Prognosis of ESD for the Superficial Esophageal Squamous Cell Carcinoma. Gastrointestinal Endoscopy 2008; 67: A182
9. Gockel I, Hansen T, Sultanov FS et al. High Prevalence of Lymph Node Metastases in pTl Esophageal Cancer: Is Local Therapy Justified? Gastroenterology 2008; 134: A-904
10. Igaki H, Kato H, Ando N et al. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage 11/111 squamous cell carcinoma of the thoracic esophagus (JCOG 9907). J Clin Oncol 2008; 26: A4510
11. Tepper J, Krasna MJ, Niedzwiecki D et al. Phase 111 trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-1092
12. Gebski V, Burmeister B, Smithers BM et al Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234
13. Boige V, Pignon J, Saint-Aubert B et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007; 25: A4510
14. Cunningham D. Allum WH. Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20
15. Di Fiore F, Lecleire S, Rigal O et al. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12: 4185-4190
16. Lordick F, Ott K, Krause BJ et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUN1CON phase II trial. Lancet Oncol 2007; 8: 797-805
17. Lecleire S, Di Fiore F, Antonietti M et al. Double Stenting of Esophagus and Airways in Patients with Locally Advanced Esophageal Cancer: Feasibility, Efficacy and Complications. Gastrointestinal Endoscopy 2006; 63: A123
18. Chadha KS, Schiff MD, Sitrin MD et al. Analysis of Clinical Outcomes of Esophageal Stent Placement for Palliation of Malignant Dysphagia. Gastrointestinal Endoscopy 2008; 67: A188
19. Chen YK. Schefter T, Newman F. Esophageal Cancer Patients Undergoing External Beam Radiation After Placement of Self-Expandable Metal Stents (SEMS): Is There a Risk of Radiation Dose Enhancement? Gastrointestinal Endoscopy 2008; 67: A184
20. Van Cutsem E, Moiseyenko VM, Tjulandin S et al. V325 Study Group. Phase HI study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997
21. Allum WH, Fogarty PJ, Stenning JP et al Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer. Proc ASCO Gl Symposi urn 2008: Abstract #9
22. Lutz MP, Wilke H, Wagener DJ et al Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemein-schaft Internistische Onkologie. J Clin Oncol 2007; 25: 2580-2585
23. Ridwelski K, Fahlke J, Kettner E et al. Docetaxel-cisplatin versus 5-fluorouracil-leukovorin-cisplatin as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study. J Clin Oncol 2008; 26: A4512
24. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-1210
25. Oettle H, Post S, Neuhaus P et al Adjuvant chemotherapy with gemci-tabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297: 267-277
26. Neuhaus P, Riess H. Post S et al. CONKO-001: Final results of the randomised, prospective, multicenter phase 111 trial of adjuvant chemotherapy with gemicitabine vs. observation in patients with resected pancreatic cancer. J Clin Oncol 2008; 26: A4504
27. Van Laethem J. Van Cutsem E, Hammel P et al Adjuvant chemotherapy alone versus chemoradiationafter curative resection for pancreatic cancer: feasibility resultsof a randomised EORTC/FFCD/GERCOR phase 1I/III study (40013/2201/00304). J Clin Oncol 2008; 26: A4514
28. Picozzi VJ, Abrams RA. Traverso LW et al. ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5-FU, and alpha-interferon. J Clin Oncol 2008; 26: A4505
29. Moore MJ. Goldstein D, Hamm J et al Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.J Clin Oncol 2007; 25: 1960-1966
30. Heinemann V, Boeck S, Hinke A et al Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8: 82
31. Vervenne W, Bennouna J, Humblet Y et al. A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 2008; 26: A4507
32. Kindler HL, Gangadhar T, Karrison T et al. Final analysis of a randomized phase II study of bevacizumab and gemcitabine plus cetuxi-mab or erlotinib in patients with advanced pancreatic cancer. J Clin Oncol 2008; 26: A4502
33. Tuinmann G, Müller L, Hossfeld D et al. A randomised phase II study of gemcitabine versus mitomycin C versus gemcitabine/mitomycin C in patients with advanced pancreatic cancer. J Clin Oncol 2008; 26: A15658
34. Pelzer U, Kubica K, Stieler J et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 2008; 26: A4508
35. Mitry E, Dahan L, Ychou M et al. LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD 0301). J Clin Oncol 2008; 26: A4513
36. Loehrer PJ, Powell ME, Cardenes HR et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008; 26: A4506
37. Chauffert B, Momex F, Bonnetain F et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. J Clin Oncol 2006; 24: A4008
38. Javle MM, Okazaki T, Evans DB et al. Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis in patients receiving neoadjuvant therapy for pancreatic cancer. J Clin Oncol 2008; 26: A4501
39. Marelli L, Stigliano R, Triantos C et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25
40. Hanks BA, Suhocki PV, DeLong DM et al. The efficacy and tolerability of transarterial chemo-embolization (TACE) compared with transarterial embolization (TAE) for patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2008; 26: A4595
41. Vit A, De Pauli F, Sponza M et al. Transarterial chemoembolization (TACE) with doxorubicin eluting beads (DEB) for the treatment of hepatocellular carcinoma (HCC). J Clin Oncol 2008; 26: A4598
42. Graf H, Jüngst C, Straub G et al. Chemoembolization Combined with Pravastatin Improves Survival in Patients with Hepatocellular Carcinoma. Digestion 2008; 78: 34-38
43. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390
44. Cheng A, Kang Y, Chen Z et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advance hepatocellular carcinoma.' J Clin Oncol 2008; 26: A4509
45. Raoul J, Santoro A, Beaugrand M et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to ECOG performance status: A subanalysis from the SHARP trial. J Clin Oncol 2008; 26: A4587
46. Sherman M, Mazzaferro V, Amadori D et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial. J Clin Oncol 2008; 26: A4584
47. Craxi A, Porta C, Sangiovanni A et al. Efficacy and safety of sorafenib in patients with alcohol-related hepatocellular carcinoma: A sub-analysis from the SHARP trial. J Clin Oncol 2008; 26: A15591
48. Abou-Alfa GK, Amadori D, Santoro A et al. Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis? J Clin Oncol 2008; 26: A4518
49. Dollinger MM, Lautenschläger C, Lesske J et al. Thymostimulin versus placebo for treatment of advanced hepatocellular carcinoma: A randomized, controlled, double-blind, multicenter study. J Clin Oncol 2008; 26: A4519
50. Kim H, Lee S, Bae S et al. Phase II study of gemcitabine and oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. J Clin Oncol 2008; 26: A15536
51. Gerber D, Dietrich D, Koeberle D et al. Clinical benefit and quality of life in patients with advanced biliary tract cancer receiving gemcita-bine plus capecitabine: Results from a multicenter phase II trial (SAKK 44/02). J Clin Oncol 2008; 26: A15531
52. Grünberger B, Schueller J, Kaczirek K et al. Efficacy results of cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with advanced or metastatic cholangiocarcinoma: A single center phase II study. J Clin Oncol 2008; 26: A4586
53. Holen KD, Mahoney MR, LoConte NK et al. Efficacy report of a multi-center phase II trial testing a biologic-only combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: A Phase II Consortium study. J Clin Oncol 2008; 26: A4522
54. Dealis C, Bertolini F, Malavasi N et al. A phase II trial of sorafenib in patients with advanced cholangiocarcinoma. J Clin Oncol 2008; 26: A4590
55. Ribic CM, Sargent DJ, Moore M] et al. Tumor microsatellite- instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257
56. Sargent DJ, Marsoni S, Thibodeau SN et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol 2008; 26: A4008
57. Reinacher-Schick AC, Kubicka S, Freier W et al. Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (Caplri/ Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J Clin Oncol 2008; 26: A4030
58. Heinemann V, Fischer von Weikersthal L, Vehling-Kaiser U et al. Randomized trial comparing cetuximab plus XELIRI versus cetuximab plus XELOX as first line treatment of patients with metastatic colorectal cancer (mCRC): A study of the german AIO CRC study group. J Clin Oncol 2008; 26: A4033
59. Artale S, Sartore-Bianchi A, Veronese SM et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008; 26: 4217-4219
60. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for pa-nitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-1634
61. Bokemeyer C, Bondarenko I, Hartmann JTet al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26: A4000
62. Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26: A2
63. Ince WL Jubb AM, Holden SN et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97: 981-989
64. Tejpar S, Peeters M, Humblet Y et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinote-can (q2w) and escalating doses of cetuximab (qlw): The EVEREST experience (preliminary data). J Clin Oncol 2008; 26: A4001
65. Loupakis F, Pollina L, Stasi I et al. Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment. J Clin Oncol 2008; 26: A4003
66. 4 ENETS Guidelines. Neuroendocrinology 2006; 84: 155-215
67. 5 ENETS Guidelines. Neuroendocrinology 2008; 87: 8-39
68. Rindi G, Klöppel G, Alhman H et al. European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401
69. Rindi G, Klöppel G, Couvelard A et al. TNM staging of midgut and hind-gut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451: 757-762
70. Pape UF, Jann H, Müller-Nordhorn J et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113: 256-265
71. Hörsch D, Prasad V, Baum RP. Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides. J Clin Oncol 2008; 26: A4517
72. Kwekkeboom DJ, de Herder WW, Kam BL et al Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26: 2124-2123
73. Kennedy AS, Dezarn WA, McNeillie P et al Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-mi-crospheres: early results in 148 patients. Am J Clin Oncol 2008; 31: 271-279
74. Rhee TK, Lewandowski RJ, Liu DM et al 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008: 247: 1029-1035
75. King J, Glenn D, Quinn R et al. Radioactive microspheres in liver metastases from neuroendocrine cancer (NETML). J Clin Oncol 2008; 26: A15541
76. Yao JC. Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26: 4311-4318
77. Yao JC, Lombard-Bohas C, Baudin E et al A phase 11 trial of daily oral RAD001 (Everolimus) in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy. ESMO 2008: Abstract 508PD
78. Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410
79. Yao JC, Phan A, HoffP M et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26: 1316-1323
80. Hobday J, Rubin J, Holen Ket al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase 11 Consortium (P2C) study. J Clin Oncol 2007: 25: A4504
81. Pavel ME. Bartel C. Heuck F et al. Open-label, non-randomized, multi-center phase II study evaluating the angiogenesis inhibitor PTK787 / ZK222584 (PTK/ZK) in patients with advanced neuroendocrine carcinomas (NEC). J Clin Oncol 2008; 26: A1468
82. Duran I, Kortmansky J, Singh D et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95: 1148-1154
83. Sung MW, Kvols L, Jacob C er al. Phase II proof-of-concept study of ati-primod in patients with advanced low-to intermediate-grade neuroendocrine carcinoma. J Clin Oncol 2008; 26: A4611
84. Varker KA, Campbell J, Shah MH. Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol 2008; 61: 661-668
85. Kulke MH, Bergsland EK, Ryan DP et al Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors, J Clin Oncol 2006; 24: 3555-3561
86. Dogliotti L, Brizzi MP, Ferrero A et al. Phase II trial of continuous/metronomic 5-fluorouracil infusion plus long acting Octreotide in advanced neuroendocrine carcinoma. J Clin Oncol 2007; 256: A15003
87. Ekeblad S, Sundin A. Janson ET et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13: 2986-2991
88. Kulke MH. Stuart K. Enzinger PC et al. Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors. J Clin Oncol 2006; 24: 401-406
89. Kulke MH, Stuart K, Earle CC et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: A4044
90. Strosberg JR, Choi J, Gardner N et al. First-line treatment of metastas-tic pancreatic endocrine carcinomas with capecitabine and temozolomide. J Clin Oncol 2008; 26: A4612
91. Bajetta E, Catena L, Procopio G et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours ? Cancer Chemother Pharmacol 2007;59:637-642
92. Venook AP, Ko AH, Tempero MA et al. Phase 11 trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors. J Clin Oncol 2008; 26: A15545
93. Kunz PL, Kuo T, Kaiser HL et al. A phase II study of capecitabine, oxaliplatin and bevacizumab for metastatic or unresectable neuroendocrine tumors: preliminary results. J Clin Oncol 2008; 26: A15502
94. Capelle LG, de Vries AC, Looman CW et al. Epidemiology of Gastric MALT Lymphoma: A Long-Term Nationwide Study in the Netherlands. Gastroenterology 2008; 134: A618
95. Fischbach W, Dietrich CG, Al-Taie OH et al. Value of Routine Capsule Endoscopy in the Strategy of Patients with Primary Gastric Non-Hodgkin's Lymphoma. Gastroenterology 2008; 134: A296
96. Fischbach W, Goebeler M, Schramm S et al. Outcome and Quality of Life Favor a Conservative Treatment of Patients with Primary Gastric NHL's. Results of a Prospective Randomized Study. Gastroenterology 2008; 134: A296
97. Wündisch T. Dieckhoff P, Gunther A et al. 10-year follow up of 120 patients with gastric MALT lymphoma after Helicobacter pylori eradication-Histological residual disease and second cancers. J Clin Oncol 2008; 26: A8536
98. Capelle LG, de Vries AC, Looman CW et al. High Adenocarcinoma Risk After Diagnosis of Gastric MALT Lymphoma: A Long-Term Nationwide Study. Gastroenterology 2008: 134: A12
99. Spadaio P, Pitini V, Toscano G et al. Clinical activity of bortezomib in relapsed or refractory gastric marginal zone b-cell lymphoma of malt type. J Clin Oncol 2008; 26: A8567
100. Salar A, Domingo-Domenech E, Estany C et al. First-line treatment with rituximab combined with intravenous or oral fludarabine for patients with extranodal mucosa associated lymphoid tissue (MALT) lymphoma. J Clin Oncol 2008; 26: A8608
101. Aguiar Bujanda D, Cabrera Suárez MA, Llorca Martínez I et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment of primary gastrointestinal B-cell lympho-ma. J Clin Oncol 2008; 26: A19536